These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 37374302)
1. The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study. Siripongboonsitti T; Tawinprai K; Cheirsilpa K; Ungtrakul T; Krisorakun W; Chotipanich C; Wimolsiri N; Noitun P; Srirattana N; Mahanonda N Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374302 [No Abstract] [Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
3. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study. Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796 [TBL] [Abstract][Full Text] [Related]
4. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial. Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363 [TBL] [Abstract][Full Text] [Related]
5. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study). Siripongboonsitti T; Ungtrakul T; Tawinprai K; Nimmol T; Buttakosa M; Sornsamdang G; Jarrusrojwuttikul T; Silapant P; Mahanonda N Int J Infect Dis; 2023 Sep; 134():211-219. PubMed ID: 37393041 [TBL] [Abstract][Full Text] [Related]
7. Ivermectin for preventing and treating COVID-19. Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930 [TBL] [Abstract][Full Text] [Related]
8. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial. Chuah CH; Chow TS; Hor CP; Cheng JT; Ker HB; Lee HG; Lee KS; Nordin N; Ng TK; Zaid M; Zaidan NZ; Abdul Wahab S; Adnan NA; Nordin N; Tee TY; Ong SM; Chidambaram SK; Mustafa M; Clin Infect Dis; 2022 Aug; 75(1):e432-e439. PubMed ID: 34849615 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial). Siripongboonsitti T; Ungtrakul T; Tawinprai K; Auewarakul C; Chartisathian W; Jansala T; Julsawad R; Soonklang K; Mahanonda N; Mahidol C Phytomedicine; 2023 Oct; 119():155018. PubMed ID: 37625206 [TBL] [Abstract][Full Text] [Related]
11. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial. Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502 [TBL] [Abstract][Full Text] [Related]
12. The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial). Siripongboonsitti T; Tawinprai K; Payoong P; Mahanonda N J Infect Public Health; 2023 Dec; 16(12):2010-2016. PubMed ID: 37890224 [TBL] [Abstract][Full Text] [Related]
13. Monitoring and Management of Home-Quarantined Patients With COVID-19 Using a WeChat-Based Telemedicine System: Retrospective Cohort Study. Xu H; Huang S; Qiu C; Liu S; Deng J; Jiao B; Tan X; Ai L; Xiao Y; Belliato M; Yan L J Med Internet Res; 2020 Jul; 22(7):e19514. PubMed ID: 32568727 [TBL] [Abstract][Full Text] [Related]
14. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study. Almoosa Z; Saad M; Qara S; Mustafa M; Mansour A; Alshab D; Alhashem J; ALKhawajah S; Alkhalifah S; ALmarzooq M; ALzain M; Anshasi N; Ahmed G; Mutair AA J Infect Public Health; 2021 Sep; 14(9):1247-1253. PubMed ID: 34464921 [TBL] [Abstract][Full Text] [Related]
15. Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia. Ikeda M; Okugawa S; Kashiwabara K; Moritoyo T; Kanno Y; Jubishi D; Hashimoto H; Okamoto K; Tsushima K; Uchida Y; Mitsumura T; Igari H; Tsutsumi T; Araoka H; Yatera K; Yamamoto Y; Nakamura Y; Otani A; Yamashita M; Wakimoto Y; Shinohara T; Adachi-Katayama M; Oyabu T; Kanematsu A; Harada S; Takeshita Y; Nakano Y; Miyazaki Y; Sakao S; Saito M; Ogura S; Yamasaki K; Kawasuji H; Hataji O; Inoue JI; Seto Y; Moriya K Int J Infect Dis; 2023 Mar; 128():355-363. PubMed ID: 36610659 [TBL] [Abstract][Full Text] [Related]
16. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial. Li J; Zhang C; Wu Z; Wang G; Zhao H Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657 [TBL] [Abstract][Full Text] [Related]
17. Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia. Mutair AA; Shamou J; Alhumaid S; Layqah L; Ahmed GY; Thoyaja K; Mohaini MA; Almahmoud S; Barry M; Khan A; Dhama K; Al-Jamea LH; Woodman A; Rabaan AA J Infect Public Health; 2022 Apr; 15(4):389-394. PubMed ID: 35299062 [TBL] [Abstract][Full Text] [Related]
18. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712 [TBL] [Abstract][Full Text] [Related]
20. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial. Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]